This inventor holds 3 USPTO granted patents. Top assignee: Becton Dickinson and Company Limited. Active years: 1999-2001.
Company Filing History:
Years Active: 1999-2001
Title: Inventor Paul A. Foxall: Innovations in Chlamydia Detection
Introduction
Paul A. Foxall is an accomplished inventor based in San Mateo, CA, who has made significant contributions to the field of medical diagnostics. With a total of three patents to his name, he has particularly focused on innovative methods for detecting Chlamydia trachomatis, a bacterium responsible for chlamydia infections.
Latest Patents
Foxall's latest patents include advanced techniques for the amplification and detection of the Chlamydia trachomatis cryptic plasmid. His innovative work has led to the identification of specific regions within the cryptic plasmid that can be used in amplification assays. This groundbreaking approach seeks to determine the presence of Chlamydia trachomatis in various samples with high specificity. The oligonucleotides he has disclosed are tailored for thermal Strand Displacement Assay (tSDA) reactions and are designed to ensure specificity for all strains of Chlamydia trachomatis while avoiding crossreactivity with other microorganisms or human DNA.
Career Highlights
Paul A. Foxall is associated with Becton Dickinson and Company Limited, where he has continued to push the boundaries of diagnostic innovation. His work not only enhances the accuracy of chlamydia testing but also contributes to improved public health outcomes.
Collaborations
Throughout his career, Foxall has collaborated with esteemed colleagues such as Dolores M. Berger and Harish Kumar. These collaborations have enabled the sharing of expertise and ideas, fostering a productive environment for developing cutting-edge diagnostic technologies.
Conclusion
As an inventor, Paul A. Foxall has demonstrated an unwavering commitment to advancing medical diagnostics through innovative inventions. His patents reflect a deep understanding of molecular biology and an eagerness to solve real-world health challenges. With ongoing collaborations and a solid foundation in research, Foxall's contributions to the field promise to have lasting impacts on the diagnosis and treatment of infectious diseases.